Herein, we demonstrated that CHCHD4 orchestrates mitochondrial oxidative phosphorylation, and antagonizes aberrant proliferation and migration of PASMCs by directly interacting with SAM50, thereby disturbing hypoxic PAH, which could be a novel target for PAH treatment (Graph). Here, SAMM50 is linked to pulmonary arterial hypertension.